Cargando…
Pathogenesis of rheumatoid arthritis: how early is early?
Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. H...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175047/ https://www.ncbi.nlm.nih.gov/pubmed/15987499 http://dx.doi.org/10.1186/ar1780 |
_version_ | 1782124498593513472 |
---|---|
author | Firestein, Gary S |
author_facet | Firestein, Gary S |
author_sort | Firestein, Gary S |
collection | PubMed |
description | Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. However, there is no guarantee that the mechanisms of late disease are identical to very early rheumatoid arthritis. Evaluation of the cytokine profile at the earliest time points after onset of symptoms could identify novel targets that prevent progression to chronic arthritis. |
format | Text |
id | pubmed-1175047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11750472005-07-14 Pathogenesis of rheumatoid arthritis: how early is early? Firestein, Gary S Arthritis Res Ther Commentary Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. However, there is no guarantee that the mechanisms of late disease are identical to very early rheumatoid arthritis. Evaluation of the cytokine profile at the earliest time points after onset of symptoms could identify novel targets that prevent progression to chronic arthritis. BioMed Central 2005 2005-06-17 /pmc/articles/PMC1175047/ /pubmed/15987499 http://dx.doi.org/10.1186/ar1780 Text en Copyright © 2005 BioMed Central Ltd |
spellingShingle | Commentary Firestein, Gary S Pathogenesis of rheumatoid arthritis: how early is early? |
title | Pathogenesis of rheumatoid arthritis: how early is early? |
title_full | Pathogenesis of rheumatoid arthritis: how early is early? |
title_fullStr | Pathogenesis of rheumatoid arthritis: how early is early? |
title_full_unstemmed | Pathogenesis of rheumatoid arthritis: how early is early? |
title_short | Pathogenesis of rheumatoid arthritis: how early is early? |
title_sort | pathogenesis of rheumatoid arthritis: how early is early? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175047/ https://www.ncbi.nlm.nih.gov/pubmed/15987499 http://dx.doi.org/10.1186/ar1780 |
work_keys_str_mv | AT firesteingarys pathogenesisofrheumatoidarthritishowearlyisearly |